# A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.

> **NCT03715725** · — · TERMINATED · sponsor: **Bayer** · enrollment: 70000 (actual)

## Conditions studied

- Non-valvular Atrial Fibrillation

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Apixaban (Eliquis)
- **DRUG:** Dabigatran etexilate (Pradaxa)
- **DRUG:** Warfarin (Marevan)

## Key facts

- **NCT ID:** NCT03715725
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2018-10-31
- **Primary completion:** 2020-01-20
- **Final completion:** 2020-01-20
- **Target enrollment:** 70000 (ACTUAL)
- **Why stopped:** After feasibility assessment and due to delays in data receipt study was terminated
- **Last updated:** 2020-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03715725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03715725, "A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03715725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*